Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

BACKGROUND: Recurrent and/or metastatic (R/M) disease develops in approximately 65% of patients with squamous cell carcinoma of the head and neck (SCCHN) and is associated with a poor prognosis. Immune checkpoint inhibitors have proven effective in multiple tumor types, including R/M SCCHN. We repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Guigay, Joël, Lee, Keun-Wook, Patel, Manish R, Daste, Amaury, Wong, Deborah J, Goel, Sanjay, Gordon, Michael S, Gutierrez, Martin, Balmanoukian, Ani, Le Tourneau, Christophe, Mita, Alain, Vansteene, Damien, Keilholz, Ulrich, Schöffski, Patrick, Grote, Hans Juergen, Zhou, Dongli, Bajars, Marcis, Penel, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524383/
https://www.ncbi.nlm.nih.gov/pubmed/34663640
http://dx.doi.org/10.1136/jitc-2021-002998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524383/
https://www.ncbi.nlm.nih.gov/pubmed/34663640
http://dx.doi.org/10.1136/jitc-2021-002998

Ejemplares similares